Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane add-on for negative symptoms in schizophrenia
NCT04521868Phase 2Completed
- Sponsor
- Central South University
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sulforaphane in schizophrenia, sponsored by Central South University. Started Aug 2020; status: completed.
02
Drugs
sulforaphane
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04521868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521868.